Research Solutions (RSSS) 10-Q 14 Feb 25 2025 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2024	Feb. 07, 2025
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Securities Act File Number	001-39256
Entity Registrant Name	RESEARCH SOLUTIONS, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	11-3797644
Entity Address, Address Line One	Address not applicable
Entity Address, City or Town	N/A
Entity Address, Postal Zip Code	N/A
Entity Address, State or Province	NV
City Area Code	310
Local Phone Number	477-0354
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	RSSS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,646,827
Entity Central Index Key	0001386301
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 7,701,155	$ 6,100,031
Accounts receivable, net of allowance of $129,895 and $68,579, respectively	7,116,055	6,879,800
Prepaid expenses and other current assets	742,166	643,553
Prepaid royalties	589,068	1,067,237
Total current assets	16,148,444	14,690,621
Non-current assets:
Property and equipment, net of accumulated depreciation of $932,773 and $922,558, respectively	63,355	88,011
Intangible assets, net of accumulated amortization of $2,129,868 and $1,535,310, respectively ($7,891,389 provisional)	10,230,439	10,764,261
Goodwill ($13,171,486 provisional)	16,345,888	16,315,888
Deposits and other assets	867	981
Total assets	42,788,993	41,859,762
Current liabilities:
Accounts payable and accrued expenses	8,104,118	8,843,612
Deferred revenue	8,853,415	9,023,848
Contingent earnout liability, current portion	3,963,956
Total current liabilities	20,921,489	17,867,460
Non-current liabilities:
Contingent earnout liability	10,741,044	12,298,114
Total liabilities	31,662,533	30,165,574
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 32,640,407 and 32,295,373 shares issued and outstanding, respectively	32,640	32,295
Additional paid-in capital	38,836,646	38,089,958
Accumulated deficit	(27,620,476)	(26,309,246)
Accumulated other comprehensive loss	(122,350)	(118,819)
Total stockholders' equity	11,126,460	11,694,188
Total liabilities and stockholders' equity	$ 42,788,993	$ 41,859,762

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Net of allowance	$ 129,895	$ 68,579
Property and equipment, net of accumulated depreciation	932,773	922,558
Intangible assets, net of accumulated amortization	2,129,868	1,535,310
Goodwill	$ 16,345,888	$ 16,315,888
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	32,640,407	32,295,373
Common stock, shares, outstanding	32,640,407	32,295,373

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenue:
Total revenue	$ 11,914,219	$ 10,313,742	$ 23,958,701	$ 20,374,713
Cost of revenue:
Total cost of revenue	6,093,126	5,829,940	12,371,732	11,859,345
Gross profit	5,821,093	4,483,802	11,586,969	8,515,368
Operating expenses:
Selling, general and administrative	5,422,013	4,748,050	10,229,103	9,818,948
Depreciation and amortization	306,233	155,749	618,328	215,369
Total operating expenses	5,728,246	4,903,799	10,847,431	10,034,317
Income (loss) from operations	92,847	(419,997)	739,538	(1,518,949)
Other income	348,999	108,194	417,524	248,505
Change in fair value of contingent earnout liability	(2,406,886)	268,232	(2,406,886)	268,232
Loss from operations before provision for income taxes	(1,965,040)	(43,571)	(1,249,824)	(1,002,212)
Provision for income taxes	(15,194)	(10,057)	(61,406)	(39,459)
Net loss	(1,980,234)	(53,628)	(1,311,230)	(1,041,671)
Other comprehensive income (loss):
Foreign currency translation	2,637	6,349	(3,531)	5,403
Comprehensive loss	$ (1,977,597)	$ (47,279)	$ (1,314,761)	$ (1,036,268)
Basic loss per common share:
Net loss per share (in dollars per share)	$ (0.07)	$ 0	$ (0.04)	$ (0.04)
Weighted average common shares outstanding	30,421,808	28,092,945	30,384,339	27,564,404
Diluted loss per common share:
Net loss per share (in dollars per share)	$ (0.07)	$ 0	$ (0.04)	$ (0.04)
Weighted average common shares outstanding	30,421,808	28,092,945	30,384,339	27,564,404
Platforms
Revenue:
Total revenue	$ 4,601,257	$ 3,125,584	$ 8,930,902	$ 5,725,776
Cost of revenue:
Total cost of revenue	619,842	486,185	1,167,009	868,799
Transactions
Revenue:
Total revenue	7,312,962	7,188,158	15,027,799	14,648,937
Cost of revenue:
Total cost of revenue	$ 5,473,284	$ 5,343,755	$ 11,204,723	$ 10,990,546

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Loss	Total
Balance at Jun. 30, 2023	$ 29,487	$ 29,941,873	$ (22,522,649)	$ (118,224)	$ 7,330,487
Balance (in shares) at Jun. 30, 2023	29,487,508
Stock options expense		61,714			61,714
Fair value of vested restricted common stock	$ 380	1,105,226			1,105,606
Fair value of vested restricted common stock (in shares)	380,000
Repurchase of common stock	$ (27)	(68,721)			(68,748)
Repurchase of common stock (in shares)	(27,104)
Common stock issued upon exercise of stock options	$ 51	(51)
Common stock issued upon exercise of stock options (in shares)	50,180
Common stock issued for acquisition of Scite	$ 2,729	6,546,905			6,549,634
Common stock issued for acquisition of Scite (in shares)	2,729,014
Modification cost of accelerated vesting of restricted common stock		20,949			20,949
Restricted common stock expense					1,126,555
Net loss for the period			(1,041,671)		(1,041,671)
Foreign currency translation				5,403	5,403
Balance at Dec. 31, 2023	$ 32,620	37,607,895	(23,564,320)	(112,821)	13,963,374
Balance (in shares) at Dec. 31, 2023	32,619,598
Balance at Sep. 30, 2023	$ 29,624	30,487,415	(23,510,692)	(119,170)	6,887,177
Balance (in shares) at Sep. 30, 2023	29,624,085
Stock options expense		44,243			44,243
Fair value of vested restricted common stock	$ 275	530,988			531,263
Fair value of vested restricted common stock (in shares)	275,000
Repurchase of common stock	$ (8)	(22,605)			(22,613)
Repurchase of common stock (in shares)	(8,501)
Common stock issued for acquisition of Scite	$ 2,729	6,546,905			6,549,634
Common stock issued for acquisition of Scite (in shares)	2,729,014
Modification cost of accelerated vesting of restricted common stock		20,949			20,949
Net loss for the period			(53,628)		(53,628)
Foreign currency translation				6,349	6,349
Balance at Dec. 31, 2023	$ 32,620	37,607,895	(23,564,320)	(112,821)	13,963,374
Balance (in shares) at Dec. 31, 2023	32,619,598
Balance at Jun. 30, 2024	$ 32,295	38,089,958	(26,309,246)	(118,819)	11,694,188
Balance (in shares) at Jun. 30, 2024	32,295,373
Stock options expense		88,045			88,045
Grant of restricted common stock	$ 590	(590)
Grant of restricted common stock (in shares)	590,000
Forfeited restricted common stock	$ (229)	229
Forfeited restricted common stock (in shares)	(228,584)
Repurchase of common stock	$ (54)	(205,224)			$ (205,278)
Repurchase of common stock (in shares)	(53,889)
Common stock issued upon exercise of stock options	$ 38	(38)
Common stock issued upon exercise of stock options (in shares)	37,507				111,821
Restricted common stock expense		864,266			$ 864,266
Net loss for the period			(1,311,230)		(1,311,230)
Foreign currency translation				(3,531)	(3,531)
Balance at Dec. 31, 2024	$ 32,640	38,836,646	(27,620,476)	(122,350)	11,126,460
Balance (in shares) at Dec. 31, 2024	32,640,407
Balance at Sep. 30, 2024	$ 32,513	38,491,610	(25,640,242)	(124,987)	12,758,894
Balance (in shares) at Sep. 30, 2024	32,513,172
Stock options expense		59,189			59,189
Fair value of vested restricted common stock		475,133			475,133
Grant of restricted common stock	$ 340	(340)
Grant of restricted common stock (in shares)	340,000
Forfeited restricted common stock	$ (180)	180
Forfeited restricted common stock (in shares)	(180,000)
Repurchase of common stock	$ (48)	(189,111)			(189,159)
Repurchase of common stock (in shares)	(48,132)
Common stock issued upon exercise of stock options	$ 15	(15)
Common stock issued upon exercise of stock options (in shares)	15,367
Net loss for the period			(1,980,234)		(1,980,234)
Foreign currency translation				2,637	2,637
Balance at Dec. 31, 2024	$ 32,640	$ 38,836,646	$ (27,620,476)	$ (122,350)	$ 11,126,460
Balance (in shares) at Dec. 31, 2024	32,640,407

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows	6 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Cash flow from operating activities:
Net loss	$ (1,311,230)	$ (1,041,671)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	618,328	215,369
Stock options expense	88,045	61,714
Restricted common stock expense	864,266	1,105,606
Modification cost of accelerated vesting of restricted common stock		20,949
Adjustment to contingent earnout liability	2,406,886	(268,232)
Changes in operating assets and liabilities:
Accounts receivable	(266,255)	(681,502)
Prepaid expenses and other current assets	(98,613)	(67,986)
Prepaid royalties	478,169	121,100
Accounts payable and accrued expenses	(737,670)	349,310
Deferred revenue	(170,433)	(241,545)
Net cash provided by (used in) operating activities	1,871,493	(426,888)
Cash flow from investing activities:
Purchase of property and equipment	(5,404)	(55,763)
Net cash used in investing activities	(5,404)	(10,079,509)
Cash flow from financing activities:
Common stock repurchase	(205,278)	(68,748)
Payment of contingent acquisition consideration	(62,560)	(278,195)
Net cash used in financing activities	(267,838)	(346,943)
Effect of exchange rate changes	2,873	5,666
Net increase (decrease) in cash and cash equivalents	1,601,124	(10,847,674)
Cash and cash equivalents, beginning of period	6,100,031	13,545,333
Cash and cash equivalents, end of period	7,701,155	2,697,659
Supplemental disclosures of cash flow information:
Cash paid for income taxes	61,406	39,459
Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	$ 30,198	36,364
Resolute
Cash flow from investing activities:
Payment for acquisition, net of cash acquired		(2,718,253)
Scite
Cash flow from investing activities:
Payment for acquisition, net of cash acquired		$ (7,305,493)

Organization, Nature of Busines

Organization, Nature of Business and Basis of Presentation	6 Months Ended
	Dec. 31, 2024
Organization, Nature of Business and Basis of Presentation
Organization, Nature of Business and Basis of Presentation	Note 1. Organization, Nature of Business and Basis of Presentation Organization Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with five wholly owned subsidiaries: Reprints Desk, Inc., (“Reprints Desk”) a Delaware corporation, including its wholly owned subsidiary Resolute Innovation, Inc., a Delaware corporation, Scite, LLC, a Delaware limited liability company, Reprints Desk Latin America S. de R.L. de C.V., an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico. Nature of Business We are a vertical software-as-a-service (“SaaS”) and artificial intelligence (“AI”) company providing software and related services to help research-intensive organizations simplify the research process, save time and money. We offer various software platforms (“Platform” or “Platforms”) that are typically sold to corporate, academic, government and individual researchers as cloud-based SaaS via auto-renewing license agreements. Corporate, academic, and government customers typically sign up under annual or multi-year agreements paid annually in advance. Individual researchers can sign up under an annual or a month-to-month agreement and are typically billed monthly. Our Platforms also facilitate the sale of published scientific, technical, and medical (“STM”) content sold as individual articles (“Transactions”) either stand alone or via one or more of the research Platform solutions we provide. When one or more of the Platform solutions are used to purchase Transactions, customers pay for those transactions through monthly billing or via credit card for individual researchers. In addition, our Platforms facilitate rights and permissions for customers to re-use content, ensuring copyright compliance for research, regulatory and marketing use cases as well as the utilization of content with AI applications and for the training of AI models. Our Platforms enable life science and other research-intensive organizations to simplify their research and development activities through our advanced search (i.e. Discovery Tools), tools to access and buy STM articles required to support their research (i.e. Access), as well as tools that manage that content across the enterprise and on an individual basis (i.e. Manage). The Platforms also include advanced AI (“Generative AI”) based assistants to help researchers understand the quality of the articles they are reviewing, speed up the review process, and to more fully understand how various research papers relate to each other. In addition to STM content, the Platforms provide additional context to the research process by including the ability to search and assimilate a variety of other types of data such as Patent, Clinical Trial, Regulatory and Competitive Intelligence data. They also typically deliver a return on investment to the customer by reducing the amount of time it takes a research organization to find, acquire and manage content, in addition to also driving down the ultimate cost per article and overall research costs over time. Platforms Our cloud-based SaaS Platforms consist of proprietary software and Internet-based interfaces sold to customers through an annual or monthly subscription fee. Legacy functionality falls into three areas. Discovery Tools – Our Scite.ai and Resolute.ai solutions facilitate search (discovery) across virtually all STM articles available. These solutions include basic search solutions and advanced search tools. These tools allow for searching and identifying relevant research and then purchasing that research through one of our other solutions. In addition, these tools increasingly enable users to find insights in other datasets adjacent to STM content, such as Clinical Trial, Patent, Life Science & MedTech Regulatory information, Competitor and Technology landscape insights, in addition to searching the customer’s internal datasets. Scite.ai includes full text search capability on most of the worlds STM content providing better search results and citation information as supporting or contrasting evidence. This powers our AI assistant and literature search engine and gives researchers better insights into any topic. The advanced search solutions are sold through a seat, enterprise, or individual license. These Platforms are deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platforms through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platforms can also be configured to satisfy a customer’s individual preferences. We leverage our Platforms’ efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage. Access – Our Article Galaxy® (“AG”) and Article Galaxy Scholar (Academic Library version) (“AGS”) solutions allow for research organizations to load their entitlements (subscriptions, discount or token packages, and their existing content library of articles) and AG/AGS manages those entitlements in the background enabling the researchers to focus on acquiring articles they need quickly and efficiently at the lowest possible cost. When used in conjunction with our Discovery Tools Platforms, customers can initiate orders, route orders based on the lowest cost to acquire, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. In addition, Article Galaxy facilitates rights and permissions for various re-use cases, including the utilization in AI applications and training of AI applications, ensuring copyright compliance for our customers. Manage – Our References solution offers a comprehensive reference management solution with built-in document delivery capabilities specifically designed to meet the collaboration and security needs of research- intensive organizations. This user-friendly Platform enables researchers to seamlessly organize their literature, collaborate with team members, and access a vast collection of scientific content. By integrating organization tools with instant access to millions of scholarly articles, our References solution streamlines the research workflow and enhances productivity for scientific professionals. AI models are integral to powering the unique insights our platforms provide as well as the user experience customers enjoy. Natural language processing (“NLP”) and AI models are used to enhance metadata, define connections between topics and content items as well as to generate data and metrics employed to enable users to rapidly identify and understand the value of content they need for their research. We also use state of the art AI models, such as Large Language Models to include Generative AI “assistants” in several parts of the research workflow today and will continually add capability as we move forward. Today we employ Generative AI technologies as a basis for our recommendation engine in our Discovery Tools, Access, and Manage Platform solutions. In addition, Generative AI based “assistants” in some of our solutions allow the researcher to ask questions about articles, groups of articles (folders), and more. We also have the capability to provide near full text search on STM content in the Scite.ai solution where the publisher gives us the rights to do so. The ability to not only mine an article’s full text but also show snippets of full text is unique to our Company and allows our Generative AI assistants to provide highly accurate results with a very low incidence of hallucinations as part of a Retrieval Augmented Generation framework focused just on STM content. We plan to release several new Platform solutions to enhance the research workflows described above and add new solutions to support the analysis functions that exist in our typical customer base. Our Platforms are generally deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platforms through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. Our Platforms can also be configured to satisfy a customer’s individual preferences. We leverage our Platforms efficiencies in scalability, stability and development costs to fuel rapid innovation and to gain a competitive advantage. Transactions We provide our researchers with a single source to the universe of published STM content that includes over 200 million existing STM journal articles for instant download, 50 million journal articles for rent, 10 million online book chapters, and 45 million only in print journal articles. In addition, we add between 2 to 4 million newly published STM articles each year. STM content is rented or sold to our customers on a per transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users and while they typically purchase the articles via one of our Platform solutions, we do have some customers that just order articles from us on behalf of end-users in their organizations. Core to many of our Platform solutions is providing our customers with ways to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour, in most cases in seconds. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws and we are expanding these services to include the use of content in AI applications and for the training of AI models. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of seconds. While a vast majority of the articles are available in electronic form, the Company also has workflows to deliver older paper-based articles through relationships we have built with libraries around the world. Principles of Consolidation The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2024 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2024
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, the valuation of goodwill and intangible assets related to the Company’s acquisitions, accruals for contingent earnout liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required. Cash denominated in Euros, British Pounds and Japanese Yen with an aggregate US Dollar equivalent of $352,026 and $630,680 at December 31, 2024 and June 30, 2024, respectively, was held by Reprints Desk in accounts at financial institutions. The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2024 and 2023. The Company has no customers that accounted for greater than 10% of accounts receivable at December 31, 2024 and June 30, 2024. The following table summarizes vendor concentrations for content cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ December 31, ​ December 31, ​ ​ 2024 2023 ​ ​ 2024 2023 ​ ​ Vendor A ​ 27 % ​ 26 % ​ 26 % ​ 25 % ​ Vendor B ​ 10 % ​ 10 % ​ 10 % ​ 11 % ​ ​ Software Costs Based on its nature, the Company’s current software development is considered research and development and is expensed as incurred. The finalization of the Company’s research and development process precipitates the commercialization and rapid deployment of new products and enhancements. The Company continuously reviews its processes and the nature of its software development costs to determine if there are changes that would meet the requirements for capitalization under ASC 350-40, Internal-use software. Revenue Recognition The Company accounts for revenue in accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual or monthly licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platforms and the transactional sale of STM content managed, sourced and delivered through the Platform. In the six months ended December 31, 2024 and 2023, the Company recognized revenue of $4,883,268 and $3,804,136 that was included in the deferred revenue at the beginning of each respective period. This revenue was recorded for the fulfillment of performance obligations related to cloud-based software subscriptions. Deferred revenue and accounts receivable was $6,424,724 and $6,153,063 as of June 30, 2023, respectively. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: ● identify the contract with a customer; ● identify the performance obligations in the contract; ● determine the transaction price; ● allocate the transaction price to performance obligations in the contract; and ● recognize revenue as the performance obligation is satisfied. Platforms We charge a subscription fee that allows customers to access and utilize certain premium features of our Platforms. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met. Revenue by Geographical Region The following table summarizes revenue by geographical region: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ December 31, ​ ​ 2024 ​ 2023 ​ United States ​ $ 6,932,120 58.2 % ​ $ 6,070,189 ​ 58.9 % Europe ​ 3,730,368 31.3 % ​ 3,301,660 32.0 % Rest of World ​ 1,251,731 10.5 % ​ 941,893 9.1 % Total ​ $ 11,914,219 100 % ​ $ 10,313,742 100 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ ​ December 31, ​ ​ ​ 2024 ​ 2023 ​ United States ​ $ 14,044,628 58.6 % ​ $ 11,931,113 ​ 58.6 % Europe ​ 7,572,800 31.6 % ​ 6,457,252 31.7 % Rest of World ​ 2,341,273 9.8 % ​ 1,986,348 9.7 % Total ​ $ 23,958,701 100 % ​ $ 20,374,713 100 % ​ Accounts Receivable by Geographical Region The following table summarizes accounts receivable by geographical region: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2024 ​ As of June 30, 2024 ​ United States $ 3,786,975 53.2 % ​ $ 4,125,696 ​ 60.0 % Europe ​ 2,417,901 34.0 % ​ 2,082,900 30.2 % Rest of World ​ 911,179 12.8 % ​ 671,204 9.8 % Total ​ $ 7,116,055 100 % ​ $ 6,879,800 100 % ​ Business Combinations The Company accounts for its business combinations using the acquisition method of accounting where the purchase consideration is allocated to the tangible and intangible assets acquired, and liabilities assumed, based on their respective fair values as of the acquisition date. The excess of the fair value of the purchase consideration over the estimated fair values of the net assets acquired is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability. Intangible Assets Amortizable finite-lived identifiable intangible assets consist of developed technology and customer relationships acquired in the acquisition of ResoluteAI effective July 28, 2023 and Scite effective December 1, 2023 (See Note 5), and are stated at cost less accumulated amortization. The developed technology and customer relationships are being amortized over the estimated average useful lives of 3 to 10 years. The Company follows ASC 360 in accounting for finite-lived intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. For the periods ended December 31, 2024 and June 30, 2024, the Company determined there were no indicators of impairment of its intangible assets. ​ Goodwill Goodwill consists of the excess of the cost of ResoluteAI and Scite (see Note 5) over the fair value of amounts assigned to assets acquired and liabilities assumed. Under the guidance of ASC 350, goodwill is not amortized, rather it is tested for impairment annually, and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss generally would be recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit and would be measured as the excess carrying value of goodwill over the derived fair value of goodwill. The Company’s policy is to perform an annual impairment testing for its reporting unit on June 30 of each fiscal year. Deferred Revenue Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer. Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's condensed consolidated balance sheets. Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers. Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the requisite service period for awards subject to time vesting conditions and the graded tranche basis for awards subject to market vesting conditions. Forfeitures are accounted for as they occur. The Company recognizes the fair value of stock-based compensation within its condensed consolidated statements of operations and comprehensive loss with classification depending on the nature of the services rendered. Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost. Foreign Currency The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $29,554 and a gain of $13,738 for the three months ended December 31, 2024 and 2023, respectively and gains of $74,686 and $7,118 for the six months ended December 31, 2024 and 2023, respectively. Cash denominated in Euros, British Pounds and Japanese Yen with an aggregate US Dollar equivalent of $352,026, and $630,680 at December 31, 2024 and June 30, 2024, respectively, was held in accounts at financial institutions. The following table summarizes the exchange rates used: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended Year Ended ​ ​ December 31, June 30, ​ 2024 2023 2024 2023 Period end Euro: US Dollar exchange rate ​ 1.04 ​ 1.10 ​ 1.07 ​ 1.09 Average period Euro: US Dollar exchange rate 1.09 1.08 ​ 1.08 1.05 ​ ​ ​ ​ ​ ​ ​ ​ ​ Period end GBP: US Dollar exchange rate ​ 1.25 ​ 1.27 ​ 1.26 ​ 1.27 Average period GBP: US Dollar exchange rate 1.29 1.25 ​ 1.26 1.20 ​ ​ ​ ​ ​ ​ Period end Mexican Peso: US Dollar exchange rate 0.05 0.06 ​ 0.05 0.06 Average period Mexican Peso: US Dollar exchange rate 0.05 0.06 ​ 0.06 0.05 ​ Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. Basic and diluted net loss per common share is the same for the three and six months ended December 31, 2024 and 2023 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ December 31, ​ December 31, ​ 2024 2023 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss available to common shareholders ​ $ (1,980,234) ​ $ (53,628) ​ $ (1,311,230) ​ $ (1,041,671) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average commons shares - basic ​ 30,421,808 ​ 28,092,945 ​ 30,384,339 ​ 27,564,404 Dilutive effect of outstanding warrants and stock options ​ — ​ — ​ — ​ — Dilutive effect of unvested restricted common stock ​ — ​ — ​ — ​ — Weighted average commons shares - diluted ​ 30,421,808 ​ 28,092,945 ​ 30,384,339 ​ 27,564,404 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) per common share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ (0.07) ​ $ 0.00 ​ $ (0.04) ​ $ (0.04) Diluted ​ $ (0.07) ​ $ 0.00 ​ $ (0.04) ​ $ (0.04) ​ 1 Fair Value of Financial Instruments Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied. A fair value hierarchy prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3 – Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if such data is available without undue cost and effort. The following table sets forth by level, within the fair value hierarchy, the Company’s assets and liabilities at fair value as of December 31, 2024 and June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2024 ​ As of June 30, 2024 ​ Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets ​ $ — ​ $ — ​ $ — $ — ​ $ — ​ $ — ​ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent earnout liability ​ $ — ​ ​ — ​ $ 14,705,000 ​ $ 14,705,000 ​ $ — ​ ​ — ​ $ 12,298,114 ​ $ 12,298,114 Total liabilities ​ $ — ​ $ — ​ $ 14,705,000 $ 14,705,000 ​ $ — ​ $ — ​ $ 12,298,114 $ 12,298,114 ​ 1 Our contingent earnout liability related to the Scite acquisition, which is further discussed in Note 5 to the condensed consolidated financial statements, is in the “Level 3” category for valuation purposes. The contingent earnout liability fair value is estimated with the assistance of a valuation specialist, using a Monte Carlo simulation of discounted future cash flows based on management’s forecast and a 10% discount rate. Due to the uncertainty of the significant unobservable inputs into the Monte Carlo simulation, actual results may differ under different estimates and assumptions. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. Recently Issued Accounting Pronouncements In November 2023, the FASB amended ASC No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” that includes requirements for interim segment disclosures and for entities operating under a single segment. The amendment is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The Company is currently assessing the impact of the adoption of ASU 2023-07 on its interim and annual disclosures. In December 2023, the FASB amended ASC 740, Income Taxes (issued under Accounting Standards Update (ASU) 2023-09, “Improvements to Income Tax Disclosures”). This ASU requires additional disclosures related to the rate reconciliation, income taxes paid and other amendments intended to enhance effectiveness and comparability. The amendment is effective for the Company beginning with its fiscal year 2026 annual disclosures. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its annual disclosures. In November 2024, the FASB issued ASU No. 2024-03 “Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40)” which requires disclosure each reporting period, in the notes to the financial statements, of specified information about certain costs and expenses. The new requirements will be effective for the Company for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2024-03 on its annual disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Line of Credit

Line of Credit	6 Months Ended
	Dec. 31, 2024
Line of Credit
Line of Credit	Note 3. Line of Credit On April 15, 2024, the Company entered into a Loan Agreement (the “PNC Loan Agreement”) with PNC Bank, National Association (“PNC”), as lender. Pursuant to the PNC Loan Agreement, the Company entered into a Revolving Line of Credit Note (the “PNC Note”) with PNC, which provides for a $500,000 secured revolving line of credit that matures on April 15, 2025 and bears interest annually at the daily SOFR rate plus 2.5%, with accrued interest due and payable monthly. The PNC Note contains customary events of default including, among other things, payment defaults, material misrepresentations, breaches of covenants, revocation of guarantee, certain bankruptcy and insolvency events. There were no outstanding borrowings under the line of credit as of December 31, 2024 and June 30, 2024, respectively.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Dec. 31, 2024
Stockholders' Equity
Stockholders' Equity	Note 4. Stockholders’ Equity Stock Options In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. From November 2019 to November 2021, the Company's stockholders approved increases in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 1,874,513 to 6,874,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of December 31, 2024, there were 416,577 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan. The following table summarizes vested and unvested stock option activity: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ All Options ​ Vested Options ​ Unvested Options ​ ​ Weighted ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ ​ Exercise ​ ​ ​ Exercise ​ ​ ​ Exercise ​ ​ Shares ​ Price ​ Shares ​ Price ​ Shares ​ Price Outstanding at June 30, 2024 2,788,625 $ 1.93 2,529,856 $ 1.85 258,769 $ 2.73 Granted 260,000 ​ ​ 2.79 — ​ ​ — 260,000 ​ ​ 2.79 Options vesting — ​ ​ — 108,306 ​ ​ 2.73 (108,306) ​ ​ 2.73 Exercised (111,821) ​ ​ 2.03 (111,821) ​ ​ 2.03 — ​ ​ — Forfeited — ​ ​ — — ​ ​ — — ​ ​ — Outstanding at December 31, 2024 2,936,804 ​ $ 2.00 2,526,341 ​ $ 1.87 410,463 ​ $ 2.77 ​ The weighted average remaining contractual life of all options outstanding as of December 31, 2024 was 5.05 years. The remaining contractual life for options vested and exercisable at December 31, 2024 was 4.33 years. Furthermore, the aggregate intrinsic value of options outstanding as of December 31, 2024 was $6,314,912, and the aggregate intrinsic value of options vested and exercisable as of December 31, 2024 was $5,747,656, in each case based on the fair value of the Company’s common stock on December 31, 2024. During the six months ended December 31, 2024, the Company granted 260,000 options to directors with a fair value of $364,000 which amount will be amortized over the vesting period. The total stock options expense during the six months ended December 31, 2024 was $88,045 and is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations and comprehensive loss. As of December 31, 2024, the amount of unrecognized compensation related to stock options was $532,276, which will be recorded as an expense in future periods. During the six months ended December 31, 2024, the Company issued 37,507 net shares of common stock upon the exercise of options underlying 111,821 shares of common stock. The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the six months ended December 31, 2024 and 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ ​ December 31, ​ ​ ​ 2024 2023 ​ ​ Expected dividend yield — % — % ​ Risk-free interest rate 4.26 % 4.00 % ​ Expected life (in years) 6 5 ​ ​ Expected volatility 46 % 50 % ​ ​ The following table presents the information regarding stock options outstanding and exercisable as of December 31, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Option ​ Remaining ​ ​ Exercise ​ Options ​ Contractual ​ Options ​ Price ​ Outstanding ​ Life (in years) ​ Exercisable $ 0.70 225,000 0.93 225,000 ​ 0.80 16,000 0.64 16,000 ​ 0.90 15,000 0.59 15,000 ​ 1.00 15,000 0.19 15,000 ​ 1.05 300,000 1.64 300,000 ​ 1.09 40,000 1.39 40,000 ​ 1.10 105,000 0.50 105,000 ​ 1.20 247,000 2.89 247,000 ​ 1.59 25,000 3.36 25,000 ​ 2.10 ​ 238,767 ​ 7.11 ​ 238,767 ​ 2.13 ​ 211,500 ​ 5.88 ​ 211,500 ​ 2.15 ​ 200,000 ​ 7.94 ​ 200,000 ​ 2.17 ​ 28,000 ​ 6.36 ​ 28,000 ​ 2.19 ​ 5,000 ​ 7.05 ​ 5,000 ​ 2.40 274,000 3.87 274,000 ​ 2.43 ​ 61,250 ​ 6.43 ​ 61,250 ​ 2.45 ​ 72,000 ​ 5.59 ​ 72,000 ​ 2.49 ​ 68,000 ​ 5.41 ​ 68,000 ​ 2.50 ​ 20,000 ​ 4.38 ​ 20,000 ​ 2.64 ​ 7,353 ​ 6.60 ​ 7,353 ​ 2.67 ​ 21,000 ​ 6.71 ​ 21,000 ​ 2.73 ​ 257,934 ​ 8.94 ​ 107,471 ​ 2.79 ​ 260,000 ​ 9.87 ​ — ​ 2.99 ​ 8,000 ​ 5.36 ​ 8,000 ​ 3.13 ​ 208,000 ​ 4.87 ​ 208,000 ​ 3.50 ​ 8,000 ​ 5.12 ​ 8,000 ​ Total ​ 2,936,804 ​ ​ ​ 2,526,341 ​ Restricted Common Stock During the six months ended December 31, 2024, the Company issued an additional 590,000 shares of restricted stock to employees, with an aggregate fair value of $1,309,240. The shares were granted, under the 2017 Plan, as restricted stock awards to key management in accordance with its long-term equity bonus program (the “LTEBP”). The LTEBP replaces the previous restricted stock compensation program for executives. It first became effective on August 19, 2022, and grants under the program span 5 years • 20% at a 30-day VWAP of $3.00 per share (vestings occurred on March 14, 2024 and December 9, 2024); ​ Upon a change of control, vesting will accelerate with respect to that portion of the award that would vest if the target 30-day VWAP was achieved at the level above the per share price in such change of control transaction. For example, if we granted an award of 100,000 shares under the LTEBP, 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.00 per share, and 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.75 per share. If the per share price in a change of control transaction was $5.00 per share, vesting would accelerate for 40,000 shares under the same award (i.e. the number of shares that would vest for our stock price achieving a 30-day VWAP of $5.25 per share, pursuant to a tier round up provision in the Plan effective upon a change in control). As a condition to receiving awards under the LTEBP, recipients will be required to hold at least 75% of all vested shares during the term of their employment. Applicable target 30-day VWAPs must be achieved within 5 years following the grant of awards under the LTEBP, and all unvested awards under the LTEBP will be forfeited upon expiration of such 5-year As the vesting of the 590,000 shares of restricted common stock under the LTEBP is subject to certain market conditions, pursuant to current accounting guidelines, the Company determined the fair value, with the assistance of a valuation specialist, to be $1,309,240, computed using the Monte Carlo simulations on a binomial model with a derived service period ranging from 0.64 to 2.33 years. The total restricted common stock expense related to amortization of the fair value of the restricted stock awards were $864,266 and $1,126,555 during the six months ended December 31, 2024 and 2023, respectively, and is included in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. As of December 31, 2024, the amount of unrecognized compensation related to issuances of restricted common stock was $1,492,847, which will be recognized as an expense in future periods. When calculating basic net income per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. From the 32,640,407 shares issued and outstanding on the condensed consolidated balance sheets, 2,093,101 shares are subject to vesting and are not considered outstanding for accounting purposes. The following table summarizes restricted common stock activity: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Number of ​ ​ ​ ​ Grant Date ​ ​ Shares ​ Fair Value ​ Fair Value Non-vested, June 30, 2024 1,957,726 ​ $ 3,075,449 ​ $ 1.57 Granted 590,000 ​ 1,309,240 ​ 2.22 Vested (226,041) ​ (571,261) ​ 2.53 Forfeited (228,584) ​ (332,450) ​ 1.45 Non-vested, December 31, 2024 2,093,101 ​ $ 3,480,978 ​ $ 1.66 ​ Common Stock Repurchases Effective as of March 19, 2024, the Compensation Committee of our Board of Directors authorized the repurchase, on the last day of each trading window during which the outstanding awards remain outstanding and otherwise in accordance with our insider trading policies, of an aggregate value not exceeding $750,000 (the “Repurchase Cap”), in addition to the prior remaining balance of outstanding common stock of $330,774 (at prices no greater than $4.00 per share) (the “Repurchase Price Cap”)) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards through the end of fiscal year 2025. Effective as of December 19, 2024, the Compensation Committee of our Board of Directors authorized an increase in the Repurchase Cap to an aggregate value not exceeding $1,500,000 and the Repurchase Price Cap to a price no greater than $5.50 per share. The actual number of shares repurchased will be determined by applicable employees in their discretion and will depend on their evaluation of market conditions and other factors. As of June 30, 2024, $346,893 remained under the current authorization to repurchase our outstanding common stock from our employees. During the six months ended December 31, 2024, the Company repurchased 53,889 shares of our common stock from employees at an average market price of approximately $3.81 per share for an aggregate amount of $205,278. As of December 31, 2024, $891,615 remains under the current authorization to repurchase our outstanding common stock from our employees. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares.

Acquisitions

Acquisitions	6 Months Ended
	Dec. 31, 2024
Acquisitions
Acquisitions	Note 5. Acquisitions FIZ On September 28, 2022, Reprints Desk entered into an asset purchase agreement with FIZ Karlsruhe – Leibniz-Institut für Informationsinfrastruktur GmbH (“FIZ”). FIZ delivers STM content pursuant to various contracts with its customers through its AutoDoc platform. FIZ agreed to assign and transfer to Reprints Desk certain of these contracts effective January 1, 2023 (the “Sold Contracts”). ​ On September 30, 2022, Reprints Desk made a non-refundable payment of $297,450 (€300,000) (the “Base Amount”) as initial consideration for the asset purchase. In September 2023, Reprints Desk paid $64,578 in contingent consideration for customers that have their Sold Contracts assumed by Reprints Desk in comparison to the trailing twelve months of revenue of all Sold Contracts (the “Base Amount Plus”). As of December 31, 2024, $30,198 in contingent consideration was recorded as a liability since it was unpaid, for customers that placed an order and have consented to have their contract assumed by Reprints Desk (the “Bonus Amount”). The Bonus Amount payments made were $31,542 and $62,560 for the three and six months ended December 31, 2024, respectively. The Bonus Amount is based upon the collectable service fee that FIZ would have received from these customers. Contingent consideration for the Bonus Amount will continue to be paid in arrears through the quarter ending December 31, 2025. ​ The current contingent consideration for the Bonus Amount is recorded as a short-term liability on the condensed consolidated balance sheets. The Base Amount, the Base Amount Plus and the Bonus Amount were recorded as intangible assets on the condensed consolidated balance sheets with an estimated average useful life of 10 years. ResoluteAI On July 28, 2023, the Company acquired 100% of the outstanding stock of Resolute Innovation, Inc. (“ResoluteAI”), a Delaware corporation, an advanced search platform that equips organizations with search, discovery and knowledge management tools that are powered by artificial intelligence (“AI”) and NLP technologies. The total purchase consideration for ResoluteAI, net of cash acquired, was approximately $4.8 million. The consideration included an initial payment of $2.8 million, a holdback of $0.1 million and a contingent earnout that had an initial fair value of $1.9 million. The Company’s revaluation of the earnout resulted in a fair value of $0 on June 30, 2024. On December 23, 2024, the Company received $275,000 funds from transaction escrow release, related to a reduction of the purchase price, and recorded as other income on the condensed consolidated statements of operations and comprehensive loss during the three and six months ended December 31, 2024. Scite On December 1, 2023, the Company acquired 100% of the outstanding stock of Scite, Inc. a Delaware corporation (“Scite”), a platform for discovering and evaluating scientific articles via an AI model to create unique “Smart Citations”. Smart Citations allow users to see how a publication has been cited by providing the context of the citation and a classification describing whether it allows for supporting or contrasting evidence for the cited claim. The total purchase consideration for Scite, net of cash acquired, was approximately $21.1 million. The consideration included an initial payment of $7.2 million in cash, $6.5 million in stock, a holdback of $0.2 million and a contingent earnout that had an initial fair value of $7.2 million. The Company’s revaluations of the earnout resulted in a fair value of $12.3 million at June 30, 2024 and $14.7 million at December 31, 2024. The following sets out the unaudited pro forma operating results for the three and six months ended December 31, 2024 and 2023 for the Company had the Scite acquisition occurred as of July 1, 2023. These amounts include amortization of intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Pro Forma (Unaudited) ​ Pro Forma (Unaudited) ​ ​ Three Months ended December 31, ​ Six Months ended December 31, ​ 2024 2023 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 11,914,219 ​ $ 11,033,441 ​ $ 23,958,701 ​ $ 21,834,349 Cost of revenue ​ 6,093,126 ​ 5,877,494 ​ 12,371,732 ​ 11,967,550 Gross profit ​ 5,821,093 ​ 5,155,947 ​ 11,586,969 ​ 9,866,799 ​ ​ ​ ​ ​ Total operating expenses ​ 5,728,246 ​ 5,524,052 ​ 10,847,431 ​ 11,197,427 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income (loss) from operations ​ 92,847 ​ (368,105) ​ 739,538 ​ (1,330,628) ​ ​ ​ ​ ​ Other income (expense) ​ (2,057,887) ​ 376,426 ​ (1,989,362) ​ 516,737 ​ ​ ​ ​ ​ Income (loss) from operations before provision for income taxes ​ (1,965,040) ​ 8,321 ​ (1,249,824) ​ (813,891) Provision for income taxes ​ (15,194) ​ (10,057) ​ (61,406) ​ (39,459) ​ ​ ​ ​ ​ Pro Forma Net loss ​ $ (1,980,234) ​ $ (1,736) ​ $ (1,311,230) ​ $ (853,350) Pro Forma Net loss per weighted average share, basic and diluted ​ $ (0.07) ​ $ — ​ $ (0.04) ​ $ (0.03) ​ The Company utilized the acquisition method of accounting for the acquisition in accordance with ASC 805, Business Combinations, and allocated the purchase price to ResoluteAI’s and Scite’s tangible assets, identifiable intangible assets, and assumed liabilities at their estimated fair values as of the date of acquisition. The fair value assigned to the developed technology and customer relationships were determined using the multi-period excess earnings method, which estimates the direct cash flow expected to be generated from the existing customers acquired. The cash flows were based on estimates used to value the acquisition, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model, as well as the weighted average cost of capital. The valuation assumptions took into consideration the Company’s estimates of customer attrition and revenue growth projections. The excess of the purchase price paid by the Company over the estimated fair value of identified tangible and intangible assets has been recorded as goodwill. Goodwill also represents the future benefits as a result of the acquisitions that the Company believes will enhance the Company’s product offerings and lineup available to both new and existing customers and generate future synergies within the software and related services business. As of this Quarterly Report on Form 10-Q, management has finalized its valuation analysis related to the Resolute and Scite acquisitions. The following table represents the Company’s allocation of the total purchase consideration to the fair value of tangible assets, identifiable intangible assets, and assumed liabilities of ResoluteAI and Scite on the date of acquisition: ​ ​ ​ ​ ​ ​ ​ ​ In thousands ResoluteAI Scite Fair value of consideration ​ ​ ​ ​ ​ ​ Cash ​ $ 2,774 ​ $ 7,217 Holdback cash paid ​ 125 ​ 175 Common Stock (2,729,014 shares at $2.40 per share) ​ — ​ 6,549 Contingent earn-out ​ ​ 1,867 ​ ​ 7,194 Total purchase price ​ 4,766 ​ 21,135 ​ ​ ​ ​ ​ ​ ​ Allocation of the consideration to the fair value of assets acquired and liabilities assumed: ​ ​ ​ ​ ​ Cash and cash equivalents ​ 59 ​ — Accounts receivable ​ 132 ​ 109 Prepaid expenses ​ 43 ​ — Accounts payable and accrued expenses ​ (33) ​ — Deferred revenue ​ ​ (649) ​ ​ (997) Other current liabilities ​ ​ (60) ​ ​ (18) Net tangible assets ​ ​ (508) ​ ​ (906) ​ ​ ​ ​ ​ ​ ​ Intangible assets: ​ ​ ​ ​ ​ ​ Developed technology ​ ​ 2,000 ​ ​ 8,800 Customer relationships ​ ​ 100 ​ ​ 70 Net identifiable intangible assets ​ ​ 2,100 ​ ​ 8,870 ​ ​ ​ ​ ​ ​ ​ Goodwill ​ ​ 3,174 ​ ​ 13,171 ​ ​ ​ ​ ​ ​ ​ Fair value of net assets acquired ​ $ 4,766 ​ $ 21,135 ​

Contingencies

Contingencies	6 Months Ended
	Dec. 31, 2024
Contingencies
Contingencies	Note 6. Contingencies Inflation Risk The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2024
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, the valuation of goodwill and intangible assets related to the Company’s acquisitions, accruals for contingent earnout liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required. Cash denominated in Euros, British Pounds and Japanese Yen with an aggregate US Dollar equivalent of $352,026 and $630,680 at December 31, 2024 and June 30, 2024, respectively, was held by Reprints Desk in accounts at financial institutions. The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2024 and 2023. The Company has no customers that accounted for greater than 10% of accounts receivable at December 31, 2024 and June 30, 2024. The following table summarizes vendor concentrations for content cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ December 31, ​ December 31, ​ ​ 2024 2023 ​ ​ 2024 2023 ​ ​ Vendor A ​ 27 % ​ 26 % ​ 26 % ​ 25 % ​ Vendor B ​ 10 % ​ 10 % ​ 10 % ​ 11 % ​
Software Costs	Software Costs Based on its nature, the Company’s current software development is considered research and development and is expensed as incurred. The finalization of the Company’s research and development process precipitates the commercialization and rapid deployment of new products and enhancements. The Company continuously reviews its processes and the nature of its software development costs to determine if there are changes that would meet the requirements for capitalization under ASC 350-40, Internal-use software.
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual or monthly licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platforms and the transactional sale of STM content managed, sourced and delivered through the Platform. In the six months ended December 31, 2024 and 2023, the Company recognized revenue of $4,883,268 and $3,804,136 that was included in the deferred revenue at the beginning of each respective period. This revenue was recorded for the fulfillment of performance obligations related to cloud-based software subscriptions. Deferred revenue and accounts receivable was $6,424,724 and $6,153,063 as of June 30, 2023, respectively. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: ● identify the contract with a customer; ● identify the performance obligations in the contract; ● determine the transaction price; ● allocate the transaction price to performance obligations in the contract; and ● recognize revenue as the performance obligation is satisfied. Platforms We charge a subscription fee that allows customers to access and utilize certain premium features of our Platforms. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met. Revenue by Geographical Region The following table summarizes revenue by geographical region: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ December 31, ​ ​ 2024 ​ 2023 ​ United States ​ $ 6,932,120 58.2 % ​ $ 6,070,189 ​ 58.9 % Europe ​ 3,730,368 31.3 % ​ 3,301,660 32.0 % Rest of World ​ 1,251,731 10.5 % ​ 941,893 9.1 % Total ​ $ 11,914,219 100 % ​ $ 10,313,742 100 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ ​ December 31, ​ ​ ​ 2024 ​ 2023 ​ United States ​ $ 14,044,628 58.6 % ​ $ 11,931,113 ​ 58.6 % Europe ​ 7,572,800 31.6 % ​ 6,457,252 31.7 % Rest of World ​ 2,341,273 9.8 % ​ 1,986,348 9.7 % Total ​ $ 23,958,701 100 % ​ $ 20,374,713 100 % ​
Accounts Receivable by Geographical Region	Accounts Receivable by Geographical Region The following table summarizes accounts receivable by geographical region: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2024 ​ As of June 30, 2024 ​ United States $ 3,786,975 53.2 % ​ $ 4,125,696 ​ 60.0 % Europe ​ 2,417,901 34.0 % ​ 2,082,900 30.2 % Rest of World ​ 911,179 12.8 % ​ 671,204 9.8 % Total ​ $ 7,116,055 100 % ​ $ 6,879,800 100 %
Business Combinations	Business Combinations The Company accounts for its business combinations using the acquisition method of accounting where the purchase consideration is allocated to the tangible and intangible assets acquired, and liabilities assumed, based on their respective fair values as of the acquisition date. The excess of the fair value of the purchase consideration over the estimated fair values of the net assets acquired is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.
Intangible Assets	Intangible Assets Amortizable finite-lived identifiable intangible assets consist of developed technology and customer relationships acquired in the acquisition of ResoluteAI effective July 28, 2023 and Scite effective December 1, 2023 (See Note 5), and are stated at cost less accumulated amortization. The developed technology and customer relationships are being amortized over the estimated average useful lives of 3 to 10 years. The Company follows ASC 360 in accounting for finite-lived intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. For the periods ended December 31, 2024 and June 30, 2024, the Company determined there were no indicators of impairment of its intangible assets.
Goodwill	Goodwill Goodwill consists of the excess of the cost of ResoluteAI and Scite (see Note 5) over the fair value of amounts assigned to assets acquired and liabilities assumed. Under the guidance of ASC 350, goodwill is not amortized, rather it is tested for impairment annually, and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss generally would be recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit and would be measured as the excess carrying value of goodwill over the derived fair value of goodwill. The Company’s policy is to perform an annual impairment testing for its reporting unit on June 30 of each fiscal year.
Deferred Revenue	Deferred Revenue Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer. Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's condensed consolidated balance sheets.
Cost of Revenue	Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the requisite service period for awards subject to time vesting conditions and the graded tranche basis for awards subject to market vesting conditions. Forfeitures are accounted for as they occur. The Company recognizes the fair value of stock-based compensation within its condensed consolidated statements of operations and comprehensive loss with classification depending on the nature of the services rendered. Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.
Foreign Currency	Foreign Currency The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $29,554 and a gain of $13,738 for the three months ended December 31, 2024 and 2023, respectively and gains of $74,686 and $7,118 for the six months ended December 31, 2024 and 2023, respectively. Cash denominated in Euros, British Pounds and Japanese Yen with an aggregate US Dollar equivalent of $352,026, and $630,680 at December 31, 2024 and June 30, 2024, respectively, was held in accounts at financial institutions. The following table summarizes the exchange rates used: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended Year Ended ​ ​ December 31, June 30, ​ 2024 2023 2024 2023 Period end Euro: US Dollar exchange rate ​ 1.04 ​ 1.10 ​ 1.07 ​ 1.09 Average period Euro: US Dollar exchange rate 1.09 1.08 ​ 1.08 1.05 ​ ​ ​ ​ ​ ​ ​ ​ ​ Period end GBP: US Dollar exchange rate ​ 1.25 ​ 1.27 ​ 1.26 ​ 1.27 Average period GBP: US Dollar exchange rate 1.29 1.25 ​ 1.26 1.20 ​ ​ ​ ​ ​ ​ Period end Mexican Peso: US Dollar exchange rate 0.05 0.06 ​ 0.05 0.06 Average period Mexican Peso: US Dollar exchange rate 0.05 0.06 ​ 0.06 0.05
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. Basic and diluted net loss per common share is the same for the three and six months ended December 31, 2024 and 2023 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ December 31, ​ December 31, ​ 2024 2023 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss available to common shareholders ​ $ (1,980,234) ​ $ (53,628) ​ $ (1,311,230) ​ $ (1,041,671) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average commons shares - basic ​ 30,421,808 ​ 28,092,945 ​ 30,384,339 ​ 27,564,404 Dilutive effect of outstanding warrants and stock options ​ — ​ — ​ — ​ — Dilutive effect of unvested restricted common stock ​ — ​ — ​ — ​ — Weighted average commons shares - diluted ​ 30,421,808 ​ 28,092,945 ​ 30,384,339 ​ 27,564,404 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) per common share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ (0.07) ​ $ 0.00 ​ $ (0.04) ​ $ (0.04) Diluted ​ $ (0.07) ​ $ 0.00 ​ $ (0.04) ​ $ (0.04) ​ 1
Fair Value of Financial Instruments	Fair Value of Financial Instruments Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied. A fair value hierarchy prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3 – Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if such data is available without undue cost and effort. The following table sets forth by level, within the fair value hierarchy, the Company’s assets and liabilities at fair value as of December 31, 2024 and June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2024 ​ As of June 30, 2024 ​ Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets ​ $ — ​ $ — ​ $ — $ — ​ $ — ​ $ — ​ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent earnout liability ​ $ — ​ ​ — ​ $ 14,705,000 ​ $ 14,705,000 ​ $ — ​ ​ — ​ $ 12,298,114 ​ $ 12,298,114 Total liabilities ​ $ — ​ $ — ​ $ 14,705,000 $ 14,705,000 ​ $ — ​ $ — ​ $ 12,298,114 $ 12,298,114 ​ 1 Our contingent earnout liability related to the Scite acquisition, which is further discussed in Note 5 to the condensed consolidated financial statements, is in the “Level 3” category for valuation purposes. The contingent earnout liability fair value is estimated with the assistance of a valuation specialist, using a Monte Carlo simulation of discounted future cash flows based on management’s forecast and a 10% discount rate. Due to the uncertainty of the significant unobservable inputs into the Monte Carlo simulation, actual results may differ under different estimates and assumptions. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB amended ASC No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” that includes requirements for interim segment disclosures and for entities operating under a single segment. The amendment is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The Company is currently assessing the impact of the adoption of ASU 2023-07 on its interim and annual disclosures. In December 2023, the FASB amended ASC 740, Income Taxes (issued under Accounting Standards Update (ASU) 2023-09, “Improvements to Income Tax Disclosures”). This ASU requires additional disclosures related to the rate reconciliation, income taxes paid and other amendments intended to enhance effectiveness and comparability. The amendment is effective for the Company beginning with its fiscal year 2026 annual disclosures. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its annual disclosures. In November 2024, the FASB issued ASU No. 2024-03 “Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40)” which requires disclosure each reporting period, in the notes to the financial statements, of specified information about certain costs and expenses. The new requirements will be effective for the Company for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2024-03 on its annual disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2024
Summary of Significant Accounting Policies
Schedule of vendor concentration risk percentage	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ December 31, ​ December 31, ​ ​ 2024 2023 ​ ​ 2024 2023 ​ ​ Vendor A ​ 27 % ​ 26 % ​ 26 % ​ 25 % ​ Vendor B ​ 10 % ​ 10 % ​ 10 % ​ 11 % ​
Schedule of revenue by geographical region	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ December 31, ​ ​ 2024 ​ 2023 ​ United States ​ $ 6,932,120 58.2 % ​ $ 6,070,189 ​ 58.9 % Europe ​ 3,730,368 31.3 % ​ 3,301,660 32.0 % Rest of World ​ 1,251,731 10.5 % ​ 941,893 9.1 % Total ​ $ 11,914,219 100 % ​ $ 10,313,742 100 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ ​ December 31, ​ ​ ​ 2024 ​ 2023 ​ United States ​ $ 14,044,628 58.6 % ​ $ 11,931,113 ​ 58.6 % Europe ​ 7,572,800 31.6 % ​ 6,457,252 31.7 % Rest of World ​ 2,341,273 9.8 % ​ 1,986,348 9.7 % Total ​ $ 23,958,701 100 % ​ $ 20,374,713 100 %
Schedule of accounts receivable by geographical region	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2024 ​ As of June 30, 2024 ​ United States $ 3,786,975 53.2 % ​ $ 4,125,696 ​ 60.0 % Europe ​ 2,417,901 34.0 % ​ 2,082,900 30.2 % Rest of World ​ 911,179 12.8 % ​ 671,204 9.8 % Total ​ $ 7,116,055 100 % ​ $ 6,879,800 100 %
Schedule of foreign currency exchange rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended Year Ended ​ ​ December 31, June 30, ​ 2024 2023 2024 2023 Period end Euro: US Dollar exchange rate ​ 1.04 ​ 1.10 ​ 1.07 ​ 1.09 Average period Euro: US Dollar exchange rate 1.09 1.08 ​ 1.08 1.05 ​ ​ ​ ​ ​ ​ ​ ​ ​ Period end GBP: US Dollar exchange rate ​ 1.25 ​ 1.27 ​ 1.26 ​ 1.27 Average period GBP: US Dollar exchange rate 1.29 1.25 ​ 1.26 1.20 ​ ​ ​ ​ ​ ​ Period end Mexican Peso: US Dollar exchange rate 0.05 0.06 ​ 0.05 0.06 Average period Mexican Peso: US Dollar exchange rate 0.05 0.06 ​ 0.06 0.05
Schedule of earnings per share, basic and diluted	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ December 31, ​ December 31, ​ 2024 2023 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss available to common shareholders ​ $ (1,980,234) ​ $ (53,628) ​ $ (1,311,230) ​ $ (1,041,671) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average commons shares - basic ​ 30,421,808 ​ 28,092,945 ​ 30,384,339 ​ 27,564,404 Dilutive effect of outstanding warrants and stock options ​ — ​ — ​ — ​ — Dilutive effect of unvested restricted common stock ​ — ​ — ​ — ​ — Weighted average commons shares - diluted ​ 30,421,808 ​ 28,092,945 ​ 30,384,339 ​ 27,564,404 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) per common share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ (0.07) ​ $ 0.00 ​ $ (0.04) ​ $ (0.04) Diluted ​ $ (0.07) ​ $ 0.00 ​ $ (0.04) ​ $ (0.04) ​ 1
Schedule of Company's assets and liabilities at fair value	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2024 ​ As of June 30, 2024 ​ Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total assets ​ $ — ​ $ — ​ $ — $ — ​ $ — ​ $ — ​ $ — $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Contingent earnout liability ​ $ — ​ ​ — ​ $ 14,705,000 ​ $ 14,705,000 ​ $ — ​ ​ — ​ $ 12,298,114 ​ $ 12,298,114 Total liabilities ​ $ — ​ $ — ​ $ 14,705,000 $ 14,705,000 ​ $ — ​ $ — ​ $ 12,298,114 $ 12,298,114 ​ 1

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2024
Stockholders' Equity
Schedule of vested and unvested stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ All Options ​ Vested Options ​ Unvested Options ​ ​ Weighted ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ ​ Exercise ​ ​ ​ Exercise ​ ​ ​ Exercise ​ ​ Shares ​ Price ​ Shares ​ Price ​ Shares ​ Price Outstanding at June 30, 2024 2,788,625 $ 1.93 2,529,856 $ 1.85 258,769 $ 2.73 Granted 260,000 ​ ​ 2.79 — ​ ​ — 260,000 ​ ​ 2.79 Options vesting — ​ ​ — 108,306 ​ ​ 2.73 (108,306) ​ ​ 2.73 Exercised (111,821) ​ ​ 2.03 (111,821) ​ ​ 2.03 — ​ ​ — Forfeited — ​ ​ — — ​ ​ — — ​ ​ — Outstanding at December 31, 2024 2,936,804 ​ $ 2.00 2,526,341 ​ $ 1.87 410,463 ​ $ 2.77
Schedule of valuation assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ ​ December 31, ​ ​ ​ 2024 2023 ​ ​ Expected dividend yield — % — % ​ Risk-free interest rate 4.26 % 4.00 % ​ Expected life (in years) 6 5 ​ ​ Expected volatility 46 % 50 % ​
Schedule of additional information regarding stock options outstanding and exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Option ​ Remaining ​ ​ Exercise ​ Options ​ Contractual ​ Options ​ Price ​ Outstanding ​ Life (in years) ​ Exercisable $ 0.70 225,000 0.93 225,000 ​ 0.80 16,000 0.64 16,000 ​ 0.90 15,000 0.59 15,000 ​ 1.00 15,000 0.19 15,000 ​ 1.05 300,000 1.64 300,000 ​ 1.09 40,000 1.39 40,000 ​ 1.10 105,000 0.50 105,000 ​ 1.20 247,000 2.89 247,000 ​ 1.59 25,000 3.36 25,000 ​ 2.10 ​ 238,767 ​ 7.11 ​ 238,767 ​ 2.13 ​ 211,500 ​ 5.88 ​ 211,500 ​ 2.15 ​ 200,000 ​ 7.94 ​ 200,000 ​ 2.17 ​ 28,000 ​ 6.36 ​ 28,000 ​ 2.19 ​ 5,000 ​ 7.05 ​ 5,000 ​ 2.40 274,000 3.87 274,000 ​ 2.43 ​ 61,250 ​ 6.43 ​ 61,250 ​ 2.45 ​ 72,000 ​ 5.59 ​ 72,000 ​ 2.49 ​ 68,000 ​ 5.41 ​ 68,000 ​ 2.50 ​ 20,000 ​ 4.38 ​ 20,000 ​ 2.64 ​ 7,353 ​ 6.60 ​ 7,353 ​ 2.67 ​ 21,000 ​ 6.71 ​ 21,000 ​ 2.73 ​ 257,934 ​ 8.94 ​ 107,471 ​ 2.79 ​ 260,000 ​ 9.87 ​ — ​ 2.99 ​ 8,000 ​ 5.36 ​ 8,000 ​ 3.13 ​ 208,000 ​ 4.87 ​ 208,000 ​ 3.50 ​ 8,000 ​ 5.12 ​ 8,000 ​ Total ​ 2,936,804 ​ ​ ​ 2,526,341
Schedule of restricted common stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ Number of ​ ​ ​ ​ Grant Date ​ ​ Shares ​ Fair Value ​ Fair Value Non-vested, June 30, 2024 1,957,726 ​ $ 3,075,449 ​ $ 1.57 Granted 590,000 ​ 1,309,240 ​ 2.22 Vested (226,041) ​ (571,261) ​ 2.53 Forfeited (228,584) ​ (332,450) ​ 1.45 Non-vested, December 31, 2024 2,093,101 ​ $ 3,480,978 ​ $ 1.66

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Dec. 31, 2024
Acquisitions
Schedule of pro forma operating results	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Pro Forma (Unaudited) ​ Pro Forma (Unaudited) ​ ​ Three Months ended December 31, ​ Six Months ended December 31, ​ 2024 2023 2024 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 11,914,219 ​ $ 11,033,441 ​ $ 23,958,701 ​ $ 21,834,349 Cost of revenue ​ 6,093,126 ​ 5,877,494 ​ 12,371,732 ​ 11,967,550 Gross profit ​ 5,821,093 ​ 5,155,947 ​ 11,586,969 ​ 9,866,799 ​ ​ ​ ​ ​ Total operating expenses ​ 5,728,246 ​ 5,524,052 ​ 10,847,431 ​ 11,197,427 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income (loss) from operations ​ 92,847 ​ (368,105) ​ 739,538 ​ (1,330,628) ​ ​ ​ ​ ​ Other income (expense) ​ (2,057,887) ​ 376,426 ​ (1,989,362) ​ 516,737 ​ ​ ​ ​ ​ Income (loss) from operations before provision for income taxes ​ (1,965,040) ​ 8,321 ​ (1,249,824) ​ (813,891) Provision for income taxes ​ (15,194) ​ (10,057) ​ (61,406) ​ (39,459) ​ ​ ​ ​ ​ Pro Forma Net loss ​ $ (1,980,234) ​ $ (1,736) ​ $ (1,311,230) ​ $ (853,350) Pro Forma Net loss per weighted average share, basic and diluted ​ $ (0.07) ​ $ — ​ $ (0.04) ​ $ (0.03)
Schedule of fair value of tangible assets, identifiable intangible assets, and assumed liabilities	​ ​ ​ ​ ​ ​ ​ ​ In thousands ResoluteAI Scite Fair value of consideration ​ ​ ​ ​ ​ ​ Cash ​ $ 2,774 ​ $ 7,217 Holdback cash paid ​ 125 ​ 175 Common Stock (2,729,014 shares at $2.40 per share) ​ — ​ 6,549 Contingent earn-out ​ ​ 1,867 ​ ​ 7,194 Total purchase price ​ 4,766 ​ 21,135 ​ ​ ​ ​ ​ ​ ​ Allocation of the consideration to the fair value of assets acquired and liabilities assumed: ​ ​ ​ ​ ​ Cash and cash equivalents ​ 59 ​ — Accounts receivable ​ 132 ​ 109 Prepaid expenses ​ 43 ​ — Accounts payable and accrued expenses ​ (33) ​ — Deferred revenue ​ ​ (649) ​ ​ (997) Other current liabilities ​ ​ (60) ​ ​ (18) Net tangible assets ​ ​ (508) ​ ​ (906) ​ ​ ​ ​ ​ ​ ​ Intangible assets: ​ ​ ​ ​ ​ ​ Developed technology ​ ​ 2,000 ​ ​ 8,800 Customer relationships ​ ​ 100 ​ ​ 70 Net identifiable intangible assets ​ ​ 2,100 ​ ​ 8,870 ​ ​ ​ ​ ​ ​ ​ Goodwill ​ ​ 3,174 ​ ​ 13,171 ​ ​ ​ ​ ​ ​ ​ Fair value of net assets acquired ​ $ 4,766 ​ $ 21,135 ​

Organization, Nature of Busin_2

Organization, Nature of Business and Basis of Presentation (Details) item in Millions	6 Months Ended
	Dec. 31, 2024 item subsidiary
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of subsidiaries | subsidiary	5
Number of existing STM articles for instant download on the platform	200
Number of existing journal articles for rent on the platform	50
Number of existing online book chapters on the platform	10
Number of existing only in print journal articles on the platform	45
Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of newly published STM articles each year	2
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of newly published STM articles each year	4

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2024 USD ($) item shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2024 USD ($) item shares	Dec. 31, 2023 USD ($) shares	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
FDIC insured amount	$ 250,000		$ 250,000
Cash and cash equivalents	$ 7,701,155		$ 7,701,155		$ 6,100,031
Number of revenue streams | item	2		2
Revenue recognized that was included in deferred revenue			$ 4,883,268	$ 3,804,136
Deferred Revenue	$ 8,853,415		8,853,415		9,023,848	$ 6,424,724
Accounts receivable	7,116,055		$ 7,116,055		6,879,800	$ 6,153,063
Estimated average useful life			10 years
Foreign currency transaction gain (loss)	$ (29,554)	$ 13,738	$ 74,686	$ 7,118
Employee Stock Option [Member]
Antidilutive securities, number | shares	1,079,176	702,416	948,345	647,902
Restricted Stock [Member]
Antidilutive securities, number | shares	2,093,101	2,679,224	2,093,101	2,679,224
Maximum | Scite | Developed Technology and Customer Relationships
Estimated average useful life			10 years
Minimum | Scite | Developed Technology and Customer Relationships
Estimated average useful life			3 years
Europe financial institutions
Cash and cash equivalents	$ 352,026		$ 352,026		$ 630,680

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Concentrations (Details) - Cost of Goods and Service Benchmark [Member] - Supplier Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Vendor A
Concentration percentage	27%	26%	26%	25%
Vendor B
Concentration percentage	10%	10%	10%	11%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Revenues	$ 11,914,219	$ 10,313,742	$ 23,958,701	$ 20,374,713
Percentage of revenue	100%	100%	100%	100%
Accounts Receivable [Member]
Revenues			$ 7,116,055		$ 6,879,800
Percentage of revenue			100%		100%
UNITED STATES
Revenues	$ 6,932,120	$ 6,070,189	$ 14,044,628	$ 11,931,113
Percentage of revenue	58.20%	58.90%	58.60%	58.60%
UNITED STATES | Accounts Receivable [Member]
Revenues			$ 3,786,975		$ 4,125,696
Percentage of revenue			53.20%		60%
Europe [Member]
Revenues	$ 3,730,368	$ 3,301,660	$ 7,572,800	$ 6,457,252
Percentage of revenue	31.30%	32%	31.60%	31.70%
Europe [Member] | Accounts Receivable [Member]
Revenues			$ 2,417,901		$ 2,082,900
Percentage of revenue			34%		30.20%
Rest of World
Revenues	$ 1,251,731	$ 941,893	$ 2,341,273	$ 1,986,348
Percentage of revenue	10.50%	9.10%	9.80%	9.70%
Rest of World | Accounts Receivable [Member]
Revenues			$ 911,179		$ 671,204
Percentage of revenue			12.80%		9.80%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Exchange rates (Details)	6 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Euro to US Dollar
Period end exchange rate	1.04	1.1	1.07	1.09
Average period exchange rate	1.09	1.08	1.08	1.05
GBP To US Dollar
Period end exchange rate	1.25	1.27	1.26	1.27
Average period exchange rate	1.29	1.25	1.26	1.2
Mexican Peso to US Dollar
Period end exchange rate	0.05	0.06	0.05	0.06
Average period exchange rate	0.05	0.06	0.06	0.05

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Net Income (Loss) Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies
Net income (loss) available to common shareholders, Basic	$ (1,980,234)	$ (53,628)	$ (1,311,230)	$ (1,041,671)
Net income (loss) available to common shareholders, Diluted			$ (1,311,230)	$ (1,041,671)
Weighted average commons shares - basic	30,421,808	28,092,945	30,384,339	27,564,404
Weighted average commons shares - diluted	30,421,808	28,092,945	30,384,339	27,564,404
Net income (loss) per common share:
Basic (in dollars per share)	$ (0.07)	$ 0	$ (0.04)	$ (0.04)
Diluted (in dollars per share)	$ (0.07)	$ 0	$ (0.04)	$ (0.04)

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Company's assets and liabilities at fair value (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Liabilities
Contingent earnout liability	$ 14,705,000		$ 14,705,000		$ 12,298,114
Total liabilities	14,705,000		14,705,000		12,298,114
Change in fair value of contingent earnout liability	2,406,886	$ (268,232)	2,406,886	$ (268,232)
Level 3
Liabilities
Contingent earnout liability	14,705,000		14,705,000		12,298,114
Total liabilities	$ 14,705,000		$ 14,705,000		$ 12,298,114

Line of Credit (Details)

Line of Credit (Details) - USD ($)	Apr. 15, 2024	Dec. 31, 2024	Jun. 30, 2024
Outstanding borrowings under line of credit		$ 0	$ 0
Revolving Credit Facility Member
Line of credit amount	$ 500,000
Line of credit facility maturity date	Apr. 15, 2025
Interest bearing rate	2.50%

Stockholders' Equity - Options

Stockholders' Equity - Options Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Nov. 17, 2021	Nov. 16, 2020	Nov. 21, 2017	Nov. 10, 2016	Nov. 09, 2016
Term number of years			5 years
Weighted average remaining contractual life of all options outstanding			5 years 18 days
Remaining contractual life for options vested and exercisable			4 years 3 months 29 days
Aggregate intrinsic value of options outstanding	$ 6,314,912		$ 6,314,912
Aggregate intrinsic value of options vested and exercisable	5,747,656		$ 5,747,656
Granted (in shares)			260,000
Fair value of stock options granted			$ 364,000
Fair value of vested stock options	59,189	$ 44,243	88,045	$ 61,714
Amount of unvested compensation related to stock options	$ 532,276		$ 532,276
Common stock issued upon exercise of stock options			111,821
Common Stock [Member]
Common stock issued upon exercise of stock options	15,367		37,507	50,180
Employee Stock Option [Member] | 2007 Plan
Number of shares authorized under the plan								7,000,000	5,000,000
Number of shares available for grant	0		0
Employee Stock Option [Member] | 2017 Plan
Number of shares authorized under the plan							1,874,513
Number of shares available for grant	416,577		416,577
Employee Stock Option [Member] | Omnibus Incentive 2017 Plan [Member]
Number of shares authorized under the plan					6,874,513	1,874,513

Stockholders' Equity - Stock op

Stockholders' Equity - Stock option Activity (Details)	6 Months Ended
	Dec. 31, 2024 $ / shares shares
Outstanding beginning balance (in shares) | shares	2,788,625
Granted (in shares) | shares	260,000
Exercised (in shares) | shares	(111,821)
Outstanding ending balance (in shares) | shares	2,936,804
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.93
Granted Weighted Average Exercise Price | $ / shares	2.79
Exercised Weighted Average Exercise Price | $ / shares	2.03
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 2
Vested Options [Member]
Outstanding beginning balance (in shares) | shares	2,529,856
Options vesting (in shares) | shares	108,306
Exercised (in shares) | shares	(111,821)
Outstanding ending balance (in shares) | shares	2,526,341
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.85
Options vesting Weighted Average Exercise Price | $ / shares	2.73
Exercised Weighted Average Exercise Price | $ / shares	2.03
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.87
Unvested Options [Member]
Outstanding beginning balance (in shares) | shares	258,769
Granted (in shares) | shares	260,000
Options vesting (in shares) | shares	108,306
Outstanding ending balance (in shares) | shares	410,463
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 2.73
Granted Weighted Average Exercise Price | $ / shares	2.79
Options vesting Weighted Average Exercise Price | $ / shares	2.73
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 2.77

Stockholders' Equity - Valuatio

Stockholders' Equity - Valuation assumptions (Details)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Maximum [Member]
Expected life (in years)	2 years 3 months 29 days
Employee Stock Option [Member]
Risk-free interest rate	4.26%	4%
Expected life (in years)	6 years	5 years
Expected volatility	46%	50%

Stockholders' Equity - Stock _2

Stockholders' Equity - Stock options by exercise price (Details)	6 Months Ended
	Dec. 31, 2024 $ / shares shares
Options Outstanding	2,936,804
Options Exercisable	2,526,341
Range One
Option Exercise Price | $ / shares	$ 0.7
Options Outstanding	225,000
Remaining Contractual Life (in years)	11 months 4 days
Options Exercisable	225,000
Range Two
Option Exercise Price | $ / shares	$ 0.8
Options Outstanding	16,000
Remaining Contractual Life (in years)	7 months 20 days
Options Exercisable	16,000
Range Three
Option Exercise Price | $ / shares	$ 0.9
Options Outstanding	15,000
Remaining Contractual Life (in years)	7 months 2 days
Options Exercisable	15,000
Range Four
Option Exercise Price | $ / shares	$ 1
Options Outstanding	15,000
Remaining Contractual Life (in years)	2 months 8 days
Options Exercisable	15,000
Range Five
Option Exercise Price | $ / shares	$ 1.05
Options Outstanding	300,000
Remaining Contractual Life (in years)	1 year 7 months 20 days
Options Exercisable	300,000
Range Six
Option Exercise Price | $ / shares	$ 1.09
Options Outstanding	40,000
Remaining Contractual Life (in years)	1 year 4 months 20 days
Options Exercisable	40,000
Range Seven
Option Exercise Price | $ / shares	$ 1.1
Options Outstanding	105,000
Remaining Contractual Life (in years)	6 months
Options Exercisable	105,000
Range Eight
Option Exercise Price | $ / shares	$ 1.2
Options Outstanding	247,000
Remaining Contractual Life (in years)	2 years 10 months 20 days
Options Exercisable	247,000
Range Nine
Option Exercise Price | $ / shares	$ 1.59
Options Outstanding	25,000
Remaining Contractual Life (in years)	3 years 4 months 9 days
Options Exercisable	25,000
Range Ten
Option Exercise Price | $ / shares	$ 2.1
Options Outstanding	238,767
Remaining Contractual Life (in years)	7 years 1 month 9 days
Options Exercisable	238,767
Range Eleven
Option Exercise Price | $ / shares	$ 2.13
Options Outstanding	211,500
Remaining Contractual Life (in years)	5 years 10 months 17 days
Options Exercisable	211,500
Range Twelve
Option Exercise Price | $ / shares	$ 2.15
Options Outstanding	200,000
Remaining Contractual Life (in years)	7 years 11 months 8 days
Options Exercisable	200,000
Range Thirteen
Option Exercise Price | $ / shares	$ 2.17
Options Outstanding	28,000
Remaining Contractual Life (in years)	6 years 4 months 9 days
Options Exercisable	28,000
Range Fourteen
Option Exercise Price | $ / shares	$ 2.19
Options Outstanding	5,000
Remaining Contractual Life (in years)	7 years 18 days
Options Exercisable	5,000
Range Fifteen
Option Exercise Price | $ / shares	$ 2.4
Options Outstanding	274,000
Remaining Contractual Life (in years)	3 years 10 months 13 days
Options Exercisable	274,000
Range Sixteen
Option Exercise Price | $ / shares	$ 2.43
Options Outstanding	61,250
Remaining Contractual Life (in years)	6 years 5 months 4 days
Options Exercisable	61,250
Range Seventeen
Option Exercise Price | $ / shares	$ 2.45
Options Outstanding	72,000
Remaining Contractual Life (in years)	5 years 7 months 2 days
Options Exercisable	72,000
Range Eighteen
Option Exercise Price | $ / shares	$ 2.49
Options Outstanding	68,000
Remaining Contractual Life (in years)	5 years 4 months 28 days
Options Exercisable	68,000
Range Nineteen
Option Exercise Price | $ / shares	$ 2.5
Options Outstanding	20,000
Remaining Contractual Life (in years)	4 years 4 months 17 days
Options Exercisable	20,000
Range Twenty
Option Exercise Price | $ / shares	$ 2.64
Options Outstanding	7,353
Remaining Contractual Life (in years)	6 years 7 months 6 days
Options Exercisable	7,353
Range Twenty One
Option Exercise Price | $ / shares	$ 2.67
Options Outstanding	21,000
Remaining Contractual Life (in years)	6 years 8 months 15 days
Options Exercisable	21,000
Range Twenty Two
Option Exercise Price | $ / shares	$ 2.73
Options Outstanding	257,934
Remaining Contractual Life (in years)	8 years 11 months 8 days
Options Exercisable	107,471
Range Twenty Three
Option Exercise Price | $ / shares	$ 2.79
Options Outstanding	260,000
Remaining Contractual Life (in years)	9 years 10 months 13 days
Range Twenty Four
Option Exercise Price | $ / shares	$ 2.99
Options Outstanding	8,000
Remaining Contractual Life (in years)	5 years 4 months 9 days
Options Exercisable	8,000
Range Twenty Five
Option Exercise Price | $ / shares	$ 3.13
Options Outstanding	208,000
Remaining Contractual Life (in years)	4 years 10 months 13 days
Options Exercisable	208,000
Range Twenty Six
Option Exercise Price | $ / shares	$ 3.5
Options Outstanding	8,000
Remaining Contractual Life (in years)	5 years 1 month 13 days
Options Exercisable	8,000

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Common Stock Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Common stock issued upon exercise of stock options			111,821
Amount recognized as expense related to stock issuance			$ 88,045	$ 61,714
Term number of years			5 years
Percentage of All Vested Shares Recipient Is Required To Hold During Employment In Order To Receive Award			75%
Granted (in shares)			260,000
Fair value of vested restricted common stock	$ 475,133	$ 531,263		1,105,606
Restricted common stock expense related to amortization of the fair value of the restricted stock awards			$ 864,266	$ 1,126,555
Common Stock, Shares, Outstanding	32,640,407		32,640,407		32,295,373
Minimum [Member]
Expected life (in years)			7 months 20 days
Maximum [Member]
Expected life (in years)			2 years 3 months 29 days
Restricted Stock [Member]
Restricted common stock under the long-term equity			590,000
Fair value of restricted common stock			$ 571,261
Fair value of shares vested			1,309,240
Forfeited, Fair Value			$ (332,450)
Forfeited, Number of shares			(228,584)
Non-vested stock	$ 3,480,978		$ 3,480,978		$ 3,075,449
Non-vested, Ending balance	2,093,101		2,093,101
Term number of years			5 years
Restricted stock to employees vested			226,041
Fair value of vested restricted common stock			$ 1,309,240
Unrecognized compensation related to issuances of restricted common stock	$ 1,492,847		$ 1,492,847
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period One [Member}
Restricted common stock under the long-term equity			100,000
Vesting percentage			20%
Volume Weighted Average Stock Price Per Share			$ 3
Restricted stock to employees vested			20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Two [Member}
Vesting percentage			20%
Volume Weighted Average Stock Price Per Share			$ 3.75
Restricted stock to employees vested			20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Three [Member}
Vesting percentage			20%
Volume Weighted Average Stock Price Per Share			$ 4.5
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Four [Member}
Vesting percentage			20%
Volume Weighted Average Stock Price Per Share			$ 5.25
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Five [Member}
Vesting percentage			20%
Volume Weighted Average Stock Price Per Share			$ 6
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Six [Member}
Volume Weighted Average Stock Price Per Share			$ 5
Restricted stock to employees vested			40,000

Stockholders' Equity - Restri_2

Stockholders' Equity - Restricted common stock (Details) - Restricted Stock [Member]	6 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Non-vested, Beginning balance | shares	1,957,726
Granted Number of shares | shares	590,000
Vested, Number of shares | shares	(226,041)
Forfeited, Number of shares | shares	(228,584)
Non-vested, Ending balance | shares	2,093,101
Non-vested, Beginning balance | $	$ 3,075,449
Granted, Fair Value | $	1,309,240
Vested, Fair Value | $	(571,261)
Forfeited, Fair Value | $	(332,450)
Non-vested, Ending balance | $	$ 3,480,978
Non-vested, Beginning Balance Weighted Average Grant Date Fair Value | $ / shares	$ 1.57
Granted Weighted Average Grant Date Fair Value | $ / shares	2.22
Vested Weighted Average Grant Date Fair Value | $ / shares	2.53
Forfeited Weighted Average Grant Date Fair Value | $ / shares	1.45
Non-vested, Ending Balance Weighted Average Grant Date Fair Value | $ / shares	$ 1.66

Stockholders' Equity - Repurcha

Stockholders' Equity - Repurchases of our common stock (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 19, 2024	Jun. 30, 2024	Mar. 19, 2024
Repurchase Cap					$ 1,500,000		$ 750,000
Amount remaining under the current authorization to repurchase	$ 891,615		$ 891,615			$ 346,893
Average Price Paid per Share			$ 3.81
Repurchase of common stock	$ 189,159	$ 22,613	$ 205,278	$ 68,748
Outstanding common stock							$ 330,774
Common Stock [Member]
Total Number of Shares Purchased	48,132	8,501	53,889	27,104
Repurchase of common stock	$ 48	$ 8	$ 54	$ 27
Publicly Announced Plans Or Programs
Repurchase cap price					$ 5.5		$ 4

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details)					1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 01, 2023 USD ($)	Jul. 28, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)
Asset Acquisition, Contingent Consideration [Line Items]
Payment for non-refundable deposit for asset acquisition			$ 297,450	€ 300,000
Funds from transaction escrow release						$ 348,999	$ 108,194	$ 417,524	$ 248,505
Contingent consideration for customers					$ 64,578
Contingent earnout fair value						3,963,956		3,963,956
Payment of bonus amount						31,542		$ 62,560
Estimated average useful life								10 years
Bonus Amount
Asset Acquisition, Contingent Consideration [Line Items]
Contingent earnout fair value						30,198		$ 30,198
Scite
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of ownership interest acquired	100%
Initial payment	$ 7,217,000
Purchase consideration, net of cash acquired	21,135,000
Holdback cash paid	175,000
Contingent earnout liability incurred	7,194,000
Cash	$ 6,549,000
Contingent earnout fair value						14,700,000		14,700,000		$ 12,300,000
Resolute AI
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of ownership interest acquired		100%
Initial payment		$ 2,774,000
Purchase consideration, net of cash acquired		4,766,000
Holdback cash paid		125,000
Contingent earnout liability incurred		$ 1,867,000
Funds from transaction escrow release						275,000		275,000
Contingent earnout fair value						$ 0		$ 0

Acquisitions - Pro forma operat

Acquisitions - Pro forma operating results (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Acquisitions
Revenue	$ 11,914,219	$ 11,033,441	$ 23,958,701	$ 21,834,349
Cost of revenue	6,093,126	5,877,494	12,371,732	11,967,550
Gross profit	5,821,093	5,155,947	11,586,969	9,866,799
Total operating expenses	5,728,246	5,524,052	10,847,431	11,197,427
Loss from operations	92,847	(368,105)	739,538	(1,330,628)
Other income (expense)	(2,057,887)	376,426	(1,989,362)	516,737
Income (loss) from operations before provision for income taxes	(1,965,040)	8,321	(1,249,824)	(813,891)
Provision for income taxes	(15,194)	(10,057)	(61,406)	(39,459)
Pro Forma Net loss	$ (1,980,234)	$ (1,736)	$ (1,311,230)	$ (853,350)
Pro Forma Net loss per weighted average share, basic (in dollars per share)	$ (0.07)		$ (0.04)	$ (0.03)

Acquisitions - Assets and liabi

Acquisitions - Assets and liabilities assumed (Details) - USD ($)			6 Months Ended
	Dec. 01, 2023	Jul. 28, 2023	Dec. 31, 2024	Jun. 30, 2024
Fair value of consideration
Contingent earn-out			$ 14,705,000	$ 12,298,114
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Goodwill			$ 16,345,888	$ 16,315,888
Resolute AI
Fair value of consideration
Cash		$ 2,774,000
Holdback cash paid		125,000
Contingent earnout liability incurred		1,867,000
Total purchase price		4,766,000
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Cash and cash equivalents		59,000
Accounts receivable		132,000
Prepaid expenses		43,000
Accounts payable and accrued expenses		(33,000)
Deferred revenue		(649,000)
Other current liabilities		(60,000)
Net tangible assets		(508,000)
Net identifiable intangible assets		2,100,000
Goodwill		3,174,000
Fair value of net assets acquired		4,766,000
Resolute AI | Developed technology
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets		2,000,000
Resolute AI | Customer relationships
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets		$ 100,000
Scite
Fair value of consideration
Cash	$ 7,217,000
Holdback cash paid	175,000
Contingent earnout liability incurred	7,194,000
Common Stock (2,729,014 shares at $2.40 per share)	6,549,000
Total purchase price	21,135,000
Common stock			2,729,014
Common stock per share			$ 2.4
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Accounts receivable	109,000
Deferred revenue	(997,000)
Other current liabilities	(18,000)
Net tangible assets	(906,000)
Net identifiable intangible assets	8,870,000
Goodwill	13,171,000
Fair value of net assets acquired	21,135,000
Scite | Developed technology
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets	8,800,000
Scite | Customer relationships
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets	$ 70,000